Asgard Therapeutics is a Swedish private biotech company exploring direct cell reprogramming technologies to develop ground-breaking cancer immunotherapies. Incorporated as a spin-off from Lund University, Asgard is pioneering gene therapy approaches based on its proprietary TrojanDC technology, designed to set in motion immune responses mediated by the biological properties of professional antigen presenting cells. Designed as an off-the-shelf gene therapy, Asgard´s approach overcomes many of the logistic and manufacturing hurdles of conventional cell-based therapies.

Asgard Therapeutic’s mission is to pioneer direct cell reprogramming for cancer immunotherapy. Our current focus is to develop scalable reprogramming technologies enabling the direct in vivo conversion of cancer cells into professional antigen-presenting dendritic cells, reinstating cancer immunity.

Our lead program is pioneering an off-the-shelf personalized treatment applicable to a spectrum of cancer indications. This seemingly paradoxical approach takes advantage of TrojanDC technology that can be administered to different patients inducing presentation of the tumor(neo) antigens and activating personalized anti-tumor responses.